US FDA Issues Import Alert on Baddi Manufacturing Plant of Glenmark Pharmaceuticals

Glenmark Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has put its manufacturing plant located at Baddi, India, under import alert. The drugs manufactured at Glenmark Pharmaceuticals at Baddi plant can now be detained without any physical examination. The US FDA inspected the facility in June 2022, and has subsequently placed it […]

Continue Reading

US FDA Approves Takeda’s Livtencity Drug For Treating Post-Transplant Cytomegalovirus (CMV) Infection

Takeda Pharmaceutical has announced that, the US FDA has given the approval to the Livtencity (maribavir) drug for the purpose of treating the adults and the pediatric patients suffering from the post-transplant CMV infection that is having a refractory to the treatment with ganciclovir, cidofovir, foscarnet or valganciclovir. More than double the proportion of the […]

Continue Reading